[HTML] spandidos-publications.com

[HTML][HTML] Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial

C Oshita, M Takikawa, A Kume… - Oncology …, 2012 - spandidos-publications.com
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because
it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell …
被引用次数：139 相关文章
[PDF] academia.edu

[PDF][PDF] Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

C OSHITA, M TAKIKAWA, A KUME, H MIYATA… - ONCOLOGY …, 2012 - academia.edu
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because
it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell …
[PDF] semanticscholar.org

[PDF][PDF] Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

C OSHITA, M TAKIKAWA, A KUME… - ONCOLOGY …, 2012 - pdfs.semanticscholar.org
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because
it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell …
[HTML] spandidos-publications.com

[HTML][HTML] Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

C Oshita, M Takikawa, A Kume… - Oncology …, 2012 - spandidos-publications.com
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because
it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell …

Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.

C Oshita, M Takikawa, A Kume, H Miyata… - Oncology …, 2012 - europepmc.org
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because
it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell …

Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

C OSHITA, M TAKIKAWA, A KUME… - Oncology …, 2012 - search.proquest.com
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because
it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell …

Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial

C Oshita, M Takikawa, A Kume, H Miyata… - Oncology …, 2012 - pubmed.ncbi.nlm.nih.gov
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because
it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell …

[引用][C] Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

C OSHITA, M TAKIKAWA, A YAMAMOTO… - Oncology …, 2012 - pascal-francis.inist.fr
Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
[HTML] nih.gov

[HTML][HTML] Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

C OSHITA, M TAKIKAWA, A KUME, H MIYATA… - Oncology …, 2012 - ncbi.nlm.nih.gov
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because
it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell …

Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

C OSHITA, M TAKIKAWA, A KUME… - ONCOLOGY …, 2012 - ingentaconnect.com
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because
it is an intractable cancer with a very poor prognosis. Previously, we tested a dendritic cell …